home / stock / msclf / msclf articles
No one has written and article on iCo Therapeutics, stock symbol MSCLF. Be the first to contribute and write an article.
News, Short Squeeze, Breakout and More Instantly...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSC...